Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D03TYT
|
||||
| Former ID |
DIB011170
|
||||
| Drug Name |
PF-03800130
|
||||
| Synonyms |
Dual dopamine D2 partial agonist/serotonin reuptake inhibitor (schizophrenia/bipolar disorder), Pfizer
|
||||
| Indication | Bipolar disorder [ICD9: 296.0, 296.1, 296.4, 296.5, 296.6, 296.7, 296.8, 300; ICD10:F31, F40-F42] | Investigative | [1] | ||
| Company |
Pfizer Inc
|
||||
| Structure |
|
Download2D MOL |
|||
| Canonical SMILES |
c1ccc(N2CCN(CC2)CCCOc2nc3c(cc2)ccc(=O)[nH]3)c2c1CCC2
|
||||
| Target and Pathway | |||||
| Target(s) | D(2) dopamine receptor | Target Info | Agonist | [1] | |
| KEGG Pathway | Rap1 signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Dopaminergic synapse | |||||
| Parkinson's disease | |||||
| Cocaine addiction | |||||
| Alcoholism | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Dopamine receptor mediated signaling pathway | |||||
| Nicotine pharmacodynamics pathway | |||||
| Reactome | Dopamine receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Hypothetical Network for Drug Addiction | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Genes and (Common) Pathways Underlying Drug Addiction | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| Nicotine Activity on Dopaminergic Neurons | |||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 215). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.